1AD6 | A:378-562 | DOMAIN A OF HUMAN RETINOBLASTOMA TUMOR SUPPRESSOR |
1E9H | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND |
1F5Q | B:6-36,B:146-252; D:6-36,D:146-252; B:37-145; D:37-145 | CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2 |
1FIN | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX |
1FVV | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR |
1G3N | C:16-34,C:148-253; G:16-34,G:148-252; C:35-147; G:35-147 | STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX |
1GUX | B:645-785; A:380-577 | RB POCKET BOUND TO E7 LXCXE MOTIF |
1H1P | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058 |
1H1Q | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094 |
1H1R | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086 |
1H1S | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102 |
1H24 | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F |
1H25 | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN |
1H26 | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53 |
1H27 | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27 |
1H28 | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107 |
1H4L | D:147-293; E:147-293 | STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX |
1JKW | A:161-261; A:11-160,A:262-287 | STRUCTURE OF CYCLIN MCS2 |
1JST | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A |
1JSU | B:181-194,B:308-432; B:195-307 | P27(KIP1)/CYCLIN A/CDK2 COMPLEX |
1KXU | A:161-261; A:11-160,A:262-286 | CYCLIN H, A POSITIVE REGULATORY SUBUNIT OF CDK ACTIVATING KINASE |
1N4M | A:564-785; B:564-785; B:380-563; A:380-563 | STRUCTURE OF RB TUMOR SUPPRESSOR BOUND TO THE TRANSACTIVATION DOMAIN OF E2F-2 |
1O9K | B:644-787; D:644-787; F:644-787; H:644-787; A:379-578; C:379-578; E:379-578; G:379-578 | CRYSTAL STRUCTURE OF THE RETINOBLASTOMA TUMOUR SUPPRESSOR PROTEIN BOUND TO E2F PEPTIDE |
1OGU | B:181-194,B:308-431; D:195-307; B:195-307; D:181-194,D:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR |
1OI9 | D:181-194,D:308-430; B:195-307; D:195-307; B:181-194,B:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
1OIU | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
1OIY | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR |
1OKV | B:181-194,B:308-431; B:195-307; D:195-307; D:181-194,D:308-432 | CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2 |
1OKW | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2 |
1OL1 | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2 |
1OL2 | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2 |
1P5E | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4,5,6,7-TETRABROMOBENZOTRIAZOLE (TBS) |
1PKD | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO-CDK2/CYCLIN A |
1QMZ | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX |
1TFB | A:208-316; A:113-207 | NMR STUDIES OF HUMAN GENERAL TRANSCRIPTION FACTOR TFIIB: DYNAMICS AND INTERACTION WITH VP16 ACTIVATION DOMAIN, 20 STRUCTURES |
1UNG | E:147-294; D:145-294 | STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN. |
1UNH | D:147-294; E:147-294 | STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE, ALOISINE AND INDIRUBIN. |
1UNL | D:145-294; E:145-294 | STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE, ALOISINE AND INDIRUBIN. |
1URC | B:181-194,B:308-431; B:195-307; D:195-307; D:181-194,D:308-432 | CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY |
1VYW | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137 |
1W98 | B:114-227; B:97-113,B:228-357 | THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E |
2B9R | A:23-134; B:23-134 | CRYSTAL STRUCTURE OF HUMAN CYCLIN B1 |
2BKZ | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611 |
2BPM | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529 |
2C4G | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514 |
2C5N | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5O | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5V | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C5X | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN |
2C6T | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR |
2CCH | D:181-194,D:308-431; B:181-194,B:308-432; B:195-307; D:195-307 | THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA-LINKED ATP ANALOGUE |
2CCI | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6 |
2CJM | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE |
2G9X | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271 |
2I40 | B:181-194,B:308-431; D:181-194,D:308-432; B:195-307; D:195-307 | CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR |
2IW6 | B:181-194,B:308-431; B:195-307; D:195-307; D:181-194,D:308-431 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
2IW8 | B:181-194,B:308-431; D:195-307; B:195-307; D:181-194,D:308-431 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V-H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR |
2IW9 | B:181-194,B:308-431; D:195-307; B:195-307; D:181-194,D:308-431 | STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR |
2JGZ | B:187-298 | CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B |
2PHG | A:208-316; A:113-207 | MODEL FOR VP16 BINDING TO TFIIB |
2R7G | A:564-785; C:564-785; A:380-563; C:380-563 | STRUCTURE OF THE RETINOBLASTOMA PROTEIN POCKET DOMAIN IN COMPLEX WITH ADENOVIRUS E1A CR1 DOMAIN |
2UUE | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
2UZB | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZD | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZE | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2UZL | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR |
2V22 | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS |
2WEV | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2WFY | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2WHB | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
2WIH | D:181-194,D:308-432; B:195-307; D:195-307; B:181-194,B:308-432 | STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125 |
2WIP | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1-METHYL-4,5-DIHYDRO-1H-PYRAZOLO[4,3-H] QUINAZOLINE-3-CARBOXYLIC ACID |
2WPA | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | OPTIMISATION OF 6,6-DIMETHYL PYRROLO 3,4-C PYRAZOLES: IDENTIFICATION OF PHA-793887, A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING |
2WXV | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(4,3-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR |
2X1N | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2, CYCLIN A THROUGH STRUCTURE GUIDED DESIGN |
3BHT | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3 |
3BHU | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5 |
3BHV | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B |
3DDP | B:181-194,B:308-432; D:181-194,D:308-438; B:195-307; D:195-307 | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8 |
3DDQ | B:181-194,B:308-432; D:181-194,D:308-439; B:195-307; D:195-307 | STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE |
3DOG | B:181-194,B:308-432; D:181-194,D:308-434; B:195-307; D:195-307 | STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1 |
3EID | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR |
3EJ1 | B:181-194,B:308-432; D:181-194,D:308-432; B:195-307; D:195-307 | CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR |
3F5X | B:181-194,B:308-432; B:195-307; D:195-307; D:181-194,D:308-432 | CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE |